AR and prostate carcinoma: Apalutamide, a high-affinity AR inhibitor, binds directly to the ligand-binding domain of AR and inhibits nuclear localization and DNA binding within prostate cancer cells (Al-Salama, 2018; Rathkopf and Scher, 2018).